- Other Post Graduate Training - Duke University School of Medicine (2013-2019)
- Internship - Duke University (2009-2010)
- Graduate School - Duke University Medical Center (2013-2019)
- Fellowship - Duke University Medical Center (2012-2015), Hematology Oncology
- Residency - Duke University Medical Center (2009-2012), Internal Medicine
- Medical School - Harvard Medical School (2005-2009)
Tian Zhang, M.D.
- Internal Medicine - Hematology/Oncology
- Genitourinary Cancer
- Kidney Cancer
Tian Zhang, M.D., M.H.S., is an Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center. She specializes in the diagnosis and treatment of genitourinary malignancies, including kidney, prostate, bladder, and testicular cancers.
Dr. Zhang earned her medical degree from the Harvard-MIT Health Sciences and Technology (HST) program at Harvard Medical School. She completed a residency in internal medicine at Duke University, where she also received advanced training through a hematology-oncology fellowship. In addition, she earned a Master of Health Sciences in the Clinical Research Training Program at Duke in 2019.
Certified by the American Board of Internal Medicine in medical oncology, she joined the UT Southwestern faculty in 2021.
Dr. Zhang is a clinical trialist and translational researcher focused on evaluating clinical development of novel therapeutics and evaluating biomarkers for genitourinary malignancies. She partners closely with a multidisciplinary team at UT Southwestern to provide data-driven clinical care for her patients.
She has gained an international reputation developing clinical trials in kidney, prostate, and bladder cancers. She serves as the study chair for PDIGREE, a phase III trial in metastatic renal cell carcinoma.
Dr. Zhang is a member of several professional organizations, including the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the European Society for Medical Oncology (ESMO).
She serves on numerous committees, including as Co-chair of the National Cancer Institute Genitourinary (GU) Steering Committee Renal Task Force and as Chair of the Chinese American Hematologist and Oncologist Network (CAHON) Academic Committee. She is a member of several ASCO clinical management guidelines committees as well as the Alliance for Clinical Trials in Oncology, GU Oncology, and Immuno-Oncology Committees.
She brings a track record of research and mentoring to UT Southwestern. She has received multiple peer-reviewed grants, a Resident Research Mentoring Award from Duke, and, notably, the 2021 Cancer Prevention & Research Institute of Texas (CPRIT) Scholar Rising Stars Award.
- American Society of Clinical Oncology
- American Association for Cancer Research
- European Society for Medical Oncology
- Society for Immunotherapy of Cancer
- Chinese American Hematologist and Oncologist Network
- CPRIT Scholar Rising Stars Award 2021, Cancer Prevention & Research Institute of Texas (CPRIT)
- Resident Research Mentoring Award 2020, Duke Department of Medicine
- Women in Cancer Immunotherapy Network Leadership Institute 2019
- Duke LEADER Program 2018
- Conquer Cancer Foundation Merit Award 2015, ASCO
- Methods in Clinical Cancer Research workshop 2014, AACR/ASCO
- Conquer Cancer Foundation Merit Award 2013, ASCO
- Molecular Biology in Clinical Oncology workshop 2013, AACR
- Medicine House Staff Community Service Award 2012, Duke University
- Phi Beta Kappa 2005, Columbia University
The search for the optimal immunotherapy sequencing in the perioperative setting of RCC in Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management
Karachaliou, G.S., Kaye, D.R., George, D.J., Zhang, T (2021), Springer
Urologic Malignancies in Immune Checkpoint Inhibitors in Cancer
Harrison, M.R., Zhang, T., McNamara, M.A., Inman, B.A. (In Review), Edited by Fumito & Ernstoff
Cancer of the Kidney in Abeloff’s Clinical Oncology, 6th Edition
McNamara, M.A., Zhang, T., Harrison, M.R., George, D.J. (2019), Elsevier
Nanomedicines: Diagnostic and therapeutic applications in radiation oncology in Precision Radiation Oncology
Caster, J.M., Zhang, T., Patel, A.N., Newman, N.J., Wang, A.Z. (2018), Rutgers University Press
Systemic Therapy for non-clear cell renal cell carcinoma in ASCO 2017 Educational Book
Zhang, T., Gong, J., Caitano, M., Pal, S.K. (2017)
Management of metastatic prostate cancer in Evidence-Based Urology, 2nd Edition
Humeniuk, M., Zhang, T., McNamara, M.A., Ramalingam, S., Harrison, M.R. (2018), Wiley, BMJ Books
Prostate cancer in Cancer Management Handbook, 17th Edition
Moul, J.W., Zhang, T., Armstrong, A.J., Lattanzi, J. (2015), UBM Medica, LLC
Evolution of clinical states of castration resistant prostate cancer in Management of Castration Resistant Prostate Cancer
Zhang, T. & Armstrong, A.J. (2015), Springer
Biochemical failure in prostate cancer in Comprehensive Textbook of Prostate Cancer
Zhang, T. & Wang, A.Z. (2011), Springer Science and Business Media
- The search for the optimal immunotherapy sequencing in the perioperative setting of RCC in Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers: Multidisciplinary Management
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
Rose TL, Harrison MR, Deal AM, Ramalingam S, Whang YE, Brower B, Dunn M, Osterman CK, Heiling HM, Bjurlin MA, Smith AB, Nielsen ME, Tan HJ, Wallen E, Woods ME, George D, Zhang T, Drier A, Kim WY, Milowsky MI, Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Oct 39 28 3140-3148
Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
Spees LP, Wheeler SB, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Leapman M, Gross CP, Dinan MA, Cancer medicine 2021 Sep
Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.
Brown LC, Desai K, Wei W, Kinsey EN, Kao C, George DJ, Rini BI, Ornstein MC, Zhang T, Journal for immunotherapy of cancer 2021 Sep 9 9
Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics.
Brady-Nicholls R, Zhang J, Zhang T, Wang AZ, Butler R, Gatenby RA, Enderling H, Neoplasia (New York, N.Y.) 2021 Sep 23 9 851-858
A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab.
Desai K, Brown L, Wei W, Tucker M, Kao C, Kinsey E, Rini B, Beckermann K, Zhang T, Ornstein MC, Targeted oncology 2021 09 16 5 633-642
A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
George DJ, Halabi S, Heath EI, Sartor AO, Sonpavde GP, Das D, Bitting RL, Berry W, Healy P, Anand M, Winters C, Riggan C, Kephart J, Wilder R, Shobe K, Rasmussen J, Milowsky MI, Fleming MT, Bearden J, Goodman M, Zhang T, Harrison MR, McNamara M, Zhang D, LaCroix BL, Kittles RA, Patierno BM, Sibley AB, Patierno SR, Owzar K, Hyslop T, Freedman JA, Armstrong AJ, Cancer 2021 Aug 127 16 2954-2965
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G, Annals of oncology : official journal of the European Society for Medical Oncology 2021 06 32 6 787-800
Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.
Wheeler SB, Spees LP, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Dinan MA, JCO oncology practice 2021 Jun OP2001082
Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.
Koontz BF, Hoffman KE, Halabi S, Healy P, Anand M, George DJ, Harrison MR, Zhang T, Berry WR, Corn PG, Lee WR, Armstrong AJ, International journal of radiation oncology, biology, physics 2021 Apr 109 5 1271-1278
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT, Cancer medicine 2021 04 10 7 2341-2349
Immunotherapy and targeted-therapy combinations mark a new era of kidney cancer treatment.
Zhang T, George DJ, Nature medicine 2021 04 27 4 586-588
Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Kao C, Powers E, Wu Y, Datto MB, Green MF, Strickler JH, Ready NE, Zhang T, Clarke JM, Clinical lung cancer 2021 Mar
An Illustrative Case of Combination Cabozantinib/Nivolumab for Progressive Metastatic Renal Cell Carcinoma (mRCC).
Kao C, George DJ, Zhang T, The oncologist 2021 03 26 3 e508-e511
Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012.
Dinan MA, Georgieva MV, Li Y, Zhang T, Harrison M, Shenolikar R, Scales CD, Journal of geriatric oncology 2021 03 12 2 298-304
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
Brown LC, Tucker MD, Sedhom R, Schwartz EB, Zhu J, Kao C, Labriola MK, Gupta RT, Marin D, Wu Y, Gupta S, Zhang T, Harrison MR, George DJ, Alva A, Antonarakis ES, Armstrong AJ, Journal for immunotherapy of cancer 2021 03 9 3
Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer.
Zhang T, Agarwal A, Almquist RG, Runyambo D, Park S, Bronson E, Boominathan R, Rao C, Anand M, Oyekunle T, Healy P, McNamara MA, Ware K, Somarelli JA, George DJ, Armstrong AJ, Biomarker research 2021 Feb 9 1 14
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.
Hwang JK, Zhang T, Wang AZ, Li Z, Journal of hematology & oncology 2021 02 14 1 38
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.
Pal SK, Tangen C, Thompson IM, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN, Lancet (London, England) 2021 02 397 10275 695-703
The Immunotherapy Landscape in Renal Cell Carcinoma.
Brown LC, Desai K, Zhang T, Ornstein MC, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2020 Dec 34 6 733-748
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.
Brown LC, Zhu J, Labriola MK, Wu Y, Cheris S, Liu X, Perkinson K, Su Z, McCall S, Huang J, Foo WC, Gupta RT, Armstrong AJ, George DJ, Harrison MR, Zhang T, Clinical genitourinary cancer 2020 Dec 18 6 509-513
Novel therapies are changing treatment paradigms in metastatic prostate cancer.
Powers E, Karachaliou GS, Kao C, Harrison MR, Hoimes CJ, George DJ, Armstrong AJ, Zhang T, Journal of hematology & oncology 2020 10 13 1 144
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.
Zhang T, Harrison MR, O'Donnell PH, Alva AS, Hahn NM, Appleman LJ, Cetnar J, Burke JM, Fleming MT, Milowsky MI, Mortazavi A, Shore N, Sonpavde GP, Schmidt EV, Bitman B, Munugalavadla V, Izumi R, Patel P, Staats J, Chan C, Weinhold KJ, George DJ, Cancer 2020 10 126 20 4485-4497
The Role of Targeted Therapy in the Management of High-Risk Resected Kidney Cancer: What Have We Learned and How Will It Inform Future Adjuvant Trials.
Brown LC, Zhang T, George DJ, Cancer journal (Sudbury, Mass.) 2020 Sep/Oct 26 5 376-381
Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.
Bakthavatsalam S, Wiangnak P, George DJ, Zhang T, Franz KJ, Bioorganic & medicinal chemistry letters 2020 06 30 11 127148
Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation.
Brady-Nicholls R, Nagy JD, Gerke TA, Zhang T, Wang AZ, Zhang J, Gatenby RA, Enderling H, Nature communications 2020 04 11 1 1750
Choosing the best approach for patients with favorable-risk metastatic renal cell carcinoma.
Zhang T, George DJ, Clinical advances in hematology & oncology : H&O 2020 Apr 18 4 204-207
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK, Zhu J, Gupta R, McCall S, Jackson J, Kong EF, White JR, Cerqueira G, Gerding K, Simmons JK, George D, Zhang T, Journal for immunotherapy of cancer 2020 Mar 8 1
Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.
Zhang T, Karsh LI, Nissenblatt MJ, Canfield SE, Clinical genitourinary cancer 2020 02 18 1 1-10
WOMENtorship: The #WomenInMedicine perspective.
Marshall AL, Dversdal RK, Murphy M, Prill DM, Zhang T, Jain S, Medical teacher 2020 02 42 2 228-230
Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.
Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, Winters C, Riggan C, Rasmussen J, Wilder R, Stein M, Frizzell B, Harrison MR, Zhang T, Lee WR, Wu Y, Koontz BF, Armstrong AJ, European urology oncology 2020 Feb
Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.
Kinsey EN, Zhang T, Armstrong AJ, Cancer journal (Sudbury, Mass.) 2020 Jan/Feb 26 1 64-75
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.
Armstrong AJ, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Berry WR, Zhang T, Harrison MR, Lu C, Chen Y, Galletti G, Schonhoft JD, Scher HI, Wenstrup R, Tagawa ST, Antonarakis ES, George DJ, Halabi S, JCO precision oncology 2020 4
The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.
Zhang T, Hwang JK, George DJ, Pal SK, Cancer treatment and research communications 2020 24 100183
Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer.
Zhu J, Tucker M, Marin D, Gupta RT, Healy P, Humeniuk M, Jarvis C, Zhang T, McNamara M, George DJ, Wu Y, Lisi S, Armstrong AJ, Urologic oncology 2019 11 37 11 813.e1-813.e9
Biologically Targeted Photo-Crosslinkable Nanopatch to Prevent Postsurgical Peritoneal Adhesion.
Mi Y, Yang F, Bloomquist C, Xia Y, Sun B, Qi Y, Wagner K, Montgomery SA, Zhang T, Wang AZ, Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2019 Oct 6 19 1900809
Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
Tucker MD, Zhu J, Marin D, Gupta RT, Gupta S, Berry WR, Ramalingam S, Zhang T, Harrison M, Wu Y, Healy P, Lisi S, George DJ, Armstrong AJ, Cancer medicine 2019 08 8 10 4644-4655
A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.
Kao C, McNamara M, Alley C, Spector N, Jauhari S, Gupta RT, Zhang T, Zhu J, Clinical genitourinary cancer 2019 06 17 3 e672-e677
Emerging therapeutic targets for patients with advanced prostate cancer.
Saad F, Shore N, Zhang T, Sharma S, Cho HK, Jacobs IA, Cancer treatment reviews 2019 Jun 76 1-9
Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.
Labriola MK, Batich KA, Zhu J, McNamara MA, Harrison MR, Armstrong AJ, George DJ, Zhang T, Clinical genitourinary cancer 2019 06 17 3 e513-e521
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
Pabla S, Conroy JM, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Hagen J, Giamo V, Andreas J, Lenzo FL, Yirong W, Dy GK, Yau E, Early A, Chen H, Bshara W, Madden KG, Shirai K, Dragnev K, Tafe LJ, Marin D, Zhu J, Clarke J, Labriola M, McCall S, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Dressler L, Steciuk M, Binns O, Kasuganti D, Shah N, Ernstoff M, Odunsi K, Kurzrock R, Gardner M, Galluzzi L, Morrison C Journal for immunotherapy of cancer 2019 Feb 7 1 27
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
Conroy JM, Pabla S, Nesline MK, Glenn ST, Papanicolau-Sengos A, Burgher B, Andreas J, Giamo V, Wang Y, Lenzo FL, Bshara W, Khalil M, Dy GK, Madden KG, Shirai K, Dragnev K, Tafe LJ, Zhu J, Labriola M, Marin D, McCall SJ, Clarke J, George DJ, Zhang T, Zibelman M, Ghatalia P, Araujo-Fernandez I, de la Cruz-Merino L, Singavi A, George B, MacKinnon AC, Thompson J, Singh R, Jacob R, Kasuganti D, Shah N, Day R, Galluzzi L, Gardner M, Morrison C Journal for immunotherapy of cancer 2019 Jan 7 1 18
The promise of immunotherapy in genitourinary malignancies.
Zhang T, Armstrong AJ, George DJ, Huang J, Precision clinical medicine 2018 Dec 1 3 97-101
Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells.
Bakthavatsalam S, Sleeper ML, Dharani A, George DJ, Zhang T, Franz KJ, Angewandte Chemie (International ed. in English) 2018 09 57 39 12780-12784
Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report.
Labriola M, Foo WC, George DJ, Zhang T, Clinical genitourinary cancer 2018 06 16 3 e509-e512
Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds.
Tian X, Werner ME, Roche KC, Hanson AD, Foote HP, Yu SK, Warner SB, Copp JA, Lara H, Wauthier EL, Caster JM, Herring LE, Zhang L, Tepper JE, Hsu DS, Zhang T, Reid LM, Wang AZ, Nature biomedical engineering 2018 06 2 6 443-452
Platinum sensitivity in metastatic prostate cancer: does histology matter?
Humeniuk MS, Gupta RT, Healy P, McNamara M, Ramalingam S, Harrison M, George D, Zhang T, Wu Y, Armstrong AJ, Prostate cancer and prostatic diseases 2018 04 21 1 92-99
Multivalent binding and biomimetic cell rolling improves the sensitivity and specificity of circulating tumor cell capture.
Myung JH, Eblan MJ, Caster JM, Park S, Poellmann MJ, Wang K, Tepper JE, Tam KA, Miller SM, Shen C, Chen RC, Zhang T, Chera B, Wang AZ, Hong S Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Mar
Clinical utility of non-EpCAM based circulating tumor cell assays.
Austin RG, Huang TJ, Wu M, Armstrong AJ, Zhang T, Advanced drug delivery reviews 2018 02 125 132-142
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, Zhang T, Journal for immunotherapy of cancer 2018 01 6 1 4
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.
Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI Journal for immunotherapy of cancer 2018 Jan 6 1 9
Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.
Zhu J, Tucker M, Wang E, Grossman JS, Armstrong AJ, George DJ, Zhang T, Clinical genitourinary cancer 2017 12 15 6 e1137-e1141
Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.
Min Y, Roche KC, Tian S, Eblan MJ, McKinnon KP, Caster JM, Chai S, Herring LE, Zhang L, Zhang T, DeSimone JM, Tepper JE, Vincent BG, Serody JS, Wang AZ Nature nanotechnology 2017 Jun
Cabozantinib in genitourinary malignancies.
Zhang T, Park SE, Hong C, George DJ, Future oncology (London, England) 2017 Apr 13 8 755-765
Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials.
Caster JM, Patel AN, Zhang T, Wang A, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 2017 01 9 1
Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.
Ramalingam S, Humeniuk MS, Hu R, Rasmussen J, Healy P, Wu Y, Harrison MR, Armstrong AJ, George DJ, Zhang T Urologic oncology 2017 Jan
Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.
Tian X, Warner SB, Wagner KT, Caster JM, Zhang T, Ohana P, Gabizon AA, Wang AZ, International journal of radiation oncology, biology, physics 2016 11 96 3 547-55
Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer.
Tian J, Rodgers Z, Min Y, Wan X, Qiu H, Mi Y, Tian X, Wagner KT, Caster JM, Qi Y, Roche K, Zhang T, Cheng J, Wang AZ Nanomedicine : nanotechnology, biology, and medicine 2016 Nov
Metastatic clear cell renal cell carcinoma: Circulating biomarkers to guide antiangiogenic and immune therapies.
Zhang T, Zhu J, George DJ, Nixon AB, Urologic oncology 2016 11 34 11 510-518
Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.
Shao Z, Wang AZ, George DJ, Zhang T, Asian journal of urology 2016 Oct 3 4 268-277
What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.
Hu R, George DJ, Zhang T, Therapeutic advances in urology 2016 Aug 8 4 272-278
Is Advanced Imaging in Early-Stage Breast Cancer Ever Warranted? Reconciling Clinical Judgment With Common Quality Measures.
Kamal A, Zhang T, Power S, Marcom PK, Journal of the National Comprehensive Cancer Network : JNCCN 2016 08 14 8 993-8
Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.
Ware KE, Somarelli JA, Schaeffer D, Li J, Zhang T, Park S, Patierno SR, Freedman J, Garcia-Blanco MA, Armstrong AJ Oncotarget 2016 Jul
Development of a Novel c-MET-Based CTC Detection Platform.
Zhang T, Boominathan R, Foulk B, Rao C, Kemeny G, Strickler JH, Abbruzzese JL, Harrison MR, Hsu DS, Healy P, Li J, Pi C, Prendergast KM, Hobbs C, Gemberling S, George DJ, Hurwitz HI, Connelly M, Garcia-Blanco MA, Armstrong AJ, Molecular cancer research : MCR 2016 06 14 6 539-47
Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
Au KM, Satterlee A, Min Y, Tian X, Kim YS, Caster JM, Zhang L, Zhang T, Huang L, Wang AZ Biomaterials 2016 Mar 82 178-93
A role for the androgen receptor in the treatment of male breast cancer.
Zhu J, Davis CT, Silberman S, Spector N, Zhang T, Critical reviews in oncology/hematology 2016 Feb 98 358-63
Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.
Zhang T, Armstrong AJ, Current oncology reports 2016 Jan 18 1 3
Comparison of Quality Oncology Practice Initiative (QOPI) Measure Adherence Between Oncology Fellows, Advanced Practice Providers, and Attending Physicians.
Zhu J, Zhang T, Shah R, Kamal AH, Kelley MJ, Journal of cancer education : the official journal of the American Association for Cancer Education 2015 Dec 30 4 774-8
Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ, Clinical genitourinary cancer 2015 Aug 13 4 392-399
Mismatch repair gone awry: Management of Lynch syndrome.
Zhang T, Boswell EL, McCall SJ, Hsu DS, Critical reviews in oncology/hematology 2015 Mar 93 3 170-9
Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
Zhang T, Zhu J, George DJ, Armstrong AJ, Expert opinion on pharmacotherapy 2015 Mar 16 4 473-85
Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
Aggarwal R, Zhang T, Small EJ, Armstrong AJ, Journal of the National Comprehensive Cancer Network : JNCCN 2014 May 12 5 719-26
Standardizing and Evaluating Transitions of Care in the Era of Duty Hour Reform: One Institution's Resident-Led Effort.
Boggan JC, Zhang T, Derienzo C, Frush K, Andolsek K, Journal of graduate medical education 2013 Dec 5 4 652-7
Clinical phenotypes of castration-resistant prostate cancer.
Zhang T, Armstrong AJ, Clinical advances in hematology & oncology : H&O 2013 Nov 11 11 707-18
PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions.
Zhang T, Das SK, Fels DR, Hansen KS, Wong TZ, Dewhirst MW, Vlahovic G, AJR. American journal of roentgenology 2013 Nov 201 5 W698-706
Prevalence and impact of correlative science in breast cancer phase II trials.
Zhang T, Schneider A, Hamilton EP, Patel K, Kamal AH, Lyman GH, Peppercorn JM, Breast cancer research and treatment 2013 Jun 139 3 845-50
Handoffs in the era of duty hours reform: a focused review and strategy to address changes in the Accreditation Council for Graduate Medical Education Common Program Requirements.
DeRienzo CM, Frush K, Barfield ME, Gopwani PR, Griffith BC, Jiang X, Mehta AI, Papavassiliou P, Rialon KL, Stephany AM, Zhang T, Andolsek KM Academic medicine : journal of the Association of American Medical Colleges 2012 Apr 87 4 403-10
Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis.
Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, Chen RC, Zhang T, Wang AZ Biomaterials 2011 Nov 32 33
- Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer.
- Clinical investigation of novel and immune-based therapeutics
- Evaluation of prognostic and predictive biomarkers in genitourinary malignancies
- Translational evaluation of therapeutic targets in genitourinary malignancies
- Genitourinary Cancer
- Kidney Cancer
- Prostate Cancer
- Bladder Cancer
- Testicular Cancer